Ras moves to stay in place

Trends in Cell Biology

Volumn 25, Issue 4, 2015, Pages 190-197

  Schmick, Malte ^a   Kraemer, Astrid ^a   Bastiaens, Philippe I H ^a,b  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

Author keywords

PDE Arl2 delivery system; Ras localization; Ras signaling; Recycling endosome; Spatial cycles

Indexed keywords

PHOSPHODIESTERASE VI; PHOSPHODIESTERASE VI DELTA; RAS PROTEIN; UNCLASSIFIED DRUG;

CELL MEMBRANE; DIFFUSION; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTO ONCOGENE; REACTION ANALYSIS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLUBILIZATION; HUMAN; MUTATION; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; PROTEIN TRANSPORT;

CELL MEMBRANE; HUMANS; MUTATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84925640217     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2015.02.004     Document Type: Review

References (71)

1. Grecco H.E., et al. Signaling from the living plasma membrane. Cell 2011, 144:897-909.
2. Geyer M., Wittinghofer A. GEFs, GAPs, GDIs and effectors: taking a closer (3D) look at the regulation of Ras-related GTP-binding proteins. Curr. Opin. Struct. Biol. 1997, 7:786-792.
3. Prior I.A., et al. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012, 72:2457-2467.
4. Seeburg P.H., et al. Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 1984, 312:71-75.
5. John J., et al. Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation reaction. J. Biol. Chem. 1988, 263:11792-11799.
6. Trahey M., McCormick F. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 1987, 238:542-545.
7. Tong L.A., et al. Structural differences between a ras oncogene protein and the normal protein. Nature 1989, 337:90-93.
8. Cox A.D., et al. Drugging the undruggable RAS: mission possible?. Nat. Rev. Drug Discov. 2014, 13:828-851.
9. Karnoub A.E., Weinberg R.A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 2008, 9:517-531.
10. Adam G., Delbruck M. Reduction of dimensionality in biological diffusion processes. Structural Chemistry and Molecular Biology 1968, 198-215. W.H. Freeman. A. Rich, N. Davidson (Eds.).
11. Schmick M., Bastiaens P.I. The interdependence of membrane shape and cellular signal processing. Cell 2014, 156:1132-1138.
12. Zamir E., et al. Oncogenic signaling from the plasma membrane. Vesicle Trafficking in Cancer 2013, 57-74. Springer. Y. Yarden, G. Tarcic (Eds.).
13. Hu J., et al. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 2013, 154:1036-1046.
14. Nan X., et al. Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:18519-18524.
15. Willumsen B.M., et al. The p21 ras C-terminus is required for transformation and membrane association. Nature 1984, 310:583-586.
16. Willumsen B.M., et al. Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J. 1984, 3:2581-2585.
17. Willumsen B.M., et al. Transforming p21 ras protein: flexibility in the major variable region linking the catalytic and membrane-anchoring domains. EMBO J. 1985, 4:2893-2896.
18. Hancock J.F., et al. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 1989, 57:1167-1177.
19. Jackson J.H., et al. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:3042-3046.
20. Casey P.J., et al. p21ras is modified by a farnesyl isoprenoid. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:8323-8327.
21. Manne V., et al. Identification and preliminary characterization of protein-cysteine farnesyltransferase. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:7541-7545.
22. Freije J.M., et al. Identification and chromosomal location of two human genes encoding enzymes potentially involved in proteolytic maturation of farnesylated proteins. Genomics 1999, 58:270-280.
23. Otto J.C., et al. Cloning and characterization of a mammalian prenyl protein-specific protease. J. Biol. Chem. 1999, 274:8379-8382.
24. Gutierrez L., et al. Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis. EMBO J. 1989, 8:1093-1098.
25. Schmidt W.K., et al. Endoplasmic reticulum membrane localization of Rce1p and Ste24p, yeast proteases involved in carboxyl-terminal CAAX protein processing and amino-terminal a-factor cleavage. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:11175-11180.
26. Dai Q., et al. Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum. J. Biol. Chem. 1998, 273:15030-15034.
27. Clarke S., et al. Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:4643-4647.
28. Schmick M., et al. KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport. Cell 2014, 157:459-471.
29. Wandinger-Ness A., Zerial M. Rab proteins and the compartmentalization of the endosomal system. Cold Spring Harb. Perspect. Biol. 2014, 6:a022616.
30. Blumer J., et al. RabGEFs are a major determinant for specific Rab membrane targeting. J. Cell Biol. 2013, 200:287-300.
31. Chandra A., et al. The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins. Nat. Cell Biol. 2012, 14:148-158.
32. Florio S.K., et al. Solubilization of membrane-bound rod phosphodiesterase by the rod phosphodiesterase recombinant delta subunit. J. Biol. Chem. 1996, 271:24036-24047.
33. Hanzal-Bayer M., et al. The complex of Arl2-GTP and PDE delta: from structure to function. EMBO J. 2002, 21:2095-2106.
34. Nancy V., et al. The delta subunit of retinal rod cGMP phosphodiesterase regulates the membrane association of Ras and Rap GTPases. J. Biol. Chem. 2002, 277:15076-15084.
35. Ismail S.A., et al. Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo. Nat. Chem. Biol. 2011, 7:942-949.
36. Chen B., et al. Endocytic sorting and recycling require membrane phosphatidylserine asymmetry maintained by TAT-1/CHAT-1. PLoS Genet. 2010, 6:e1001235.
37. Magee A.I., et al. Dynamic fatty acylation of p21N-ras. EMBO J. 1987, 6:3353-3357.
38. Camp L.A., Hofmann S.L. Purification and properties of a palmitoyl-protein thioesterase that cleaves palmitate from H-Ras. J. Biol. Chem. 1993, 268:22566-22574.
39. Vartak N., et al. The autodepalmitoylating activity of APT maintains the spatial organization of palmitoylated membrane proteins. Biophys. J. 2014, 106:93-105.
40. Dekker F.J., et al. Small-molecule inhibition of APT1 affects Ras localization and signaling. Nat. Chem. Biol. 2010, 6:449-456.
41. Rocks O., et al. An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. Science 2005, 307:1746-1752.
42. Rocks O., et al. The palmitoylation machinery is a spatially organizing system for peripheral membrane proteins. Cell 2010, 141:458-471.
43. Goodwin J.S., et al. Depalmitoylated Ras traffics to and from the Golgi complex via a nonvesicular pathway. J. Cell Biol. 2005, 170:261-272.
44. Schroeder H., et al. S-Acylation and plasma membrane targeting of the farnesylated carboxyl-terminal peptide of N-ras in mammalian fibroblasts. Biochemistry 1997, 36:13102-13109.
45. Lorentzen A., et al. Regulation of Ras localization by acylation enables a mode of intracellular signal propagation. Sci. Signal. 2010, 3:ra68.
46. Fehrenbacher N., et al. Ras/MAPK signaling from endomembranes. Mol. Oncol. 2009, 3:297-307.
47. Sancak Y., et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008, 320:1496-1501.
48. Sancak Y., et al. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 2010, 141:290-303.
49. Jewell J.L., et al. Amino acid signalling upstream of mTOR. Nat. Rev. Mol. Cell Biol. 2013, 14:133-139.
50. Inoki K., et al. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003, 17:1829-1834.
51. Tee A.R., et al. Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 2003, 13:1259-1268.
52. Baines A.T., et al. Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem. 2011, 3:1787-1808.
53. Spiegel J., et al. Small-molecule modulation of Ras signaling. Nat. Chem. Biol. 2014, 10:613-622.
54. Berndt N., et al. Targeting protein prenylation for cancer therapy. Nat. Rev. Cancer 2011, 11:775-791.
55. James G.L., et al. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem. 1995, 270:6221-6226.
56. Fiordalisi J.J., et al. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors. J. Biol. Chem. 2003, 278:41718-41727.
57. Sousa S.F., et al. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr. Med. Chem. 2008, 15:1478-1492.
58. Schlitzer M., et al. Non-peptidic, non-prenylic inhibitors of the prenyl protein-specific protease Rce1. Bioorg. Med. Chem. Lett. 2001, 11:425-427.
59. Chen Y. Selective inhibition of ras-transformed cell growth by a novel fatty acid-based chloromethyl ketone designed to target Ras endoprotease. Ann. N. Y. Acad. Sci. 1999, 886:103-108.
60. Winter-Vann A.M., et al. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:4336-4341.
61. Lau H.Y., et al. An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo. Cancer Biol. Ther. 2014, 15:1280-1291.
62. Xu J., et al. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood 2012, 119:1032-1035.
63. Ahearn I.M., et al. FKBP12 binds to acylated H-ras and promotes depalmitoylation. Mol. Cell 2011, 41:173-185.
64. Tom C.T., Martin B.R. Fat chance! Getting a grip on a slippery modification. ACS Chem. Biol. 2013, 8:46-57.
65. Ducker C.E., et al. Discovery and characterization of inhibitors of human palmitoyl acyltransferases. Mol. Cancer Ther. 2006, 5:1647-1659.
66. Jennings B.C., et al. 2-Bromopalmitate and 2-(2-hydroxy-5-nitro-benzylidene)-benzo[b]thiophen-3-one inhibit DHHC-mediated palmitoylation in vitro. J. Lipid Res. 2009, 50:233-242.
67. Zimmermann G., et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 2013, 497:638-642.
68. Bivona T.G., et al. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol. Cell 2006, 21:481-493.
69. Cho K.J., et al. Staurosporines disrupt phosphatidylserine trafficking and mislocalize Ras proteins. J. Biol. Chem. 2012, 287:43573-43584.
70. Kinkhabwala A., Bastiaens P.I. Spatial aspects of intracellular information processing. Curr. Opin. Genet. Dev. 2010, 20:31-40.
71. Jura N., et al. Differential modification of Ras proteins by ubiquitination. Mol. Cell 2006, 21:679-687.